Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Parameter: Assembly | Reported procedure / limitation: Organic lipid solution and aqueous mRNA combined using a microfluidic mixer, followed by PBS dialysis. | Source: Methods; solvent identity, buffer pH, phase ratio and total flow not specified in the reviewed passage
Parameter: RNA ratio | Reported procedure / limitation: Reported lipid:mRNA mass ratio 10:1; the passage does not explicitly identify total lipid versus ionizable lipid as the numerator. | Source: Methods; not treated as N/P
Parameter: Local delivery vehicle | Reported procedure / limitation: All in vivo formulations were mixed with Pluronic F127 solution to prolong colonic residence. The concentration is not established in the reviewed passage. | Source: Methods: in vivo delivery
Parameter: Frozen-storage procedure | Reported procedure / limitation: 10 wt% sucrose in Tris and liquid-nitrogen freezing are discussed separately from the dosing formulation. | Source: Methods; do not assume the final rectal formulation has the same buffer composition
Measurement / batch: Composition convention | Reported result: 20:30:40:0.75 is explicitly a molar ratio, not a 100% table | Evidence context: Methods
Measurement / batch: Physical properties | Reported result: Individual particle-size / PDI values should be read for the corresponding formulation in Fig. 1 and SI | Evidence context: No single value is inferred for every MP2/cargo batch
Measurement / batch: Reporter versus therapeutic cargo | Reported result: Fluc, GFP, Cre and IL-35 experiments are distinct | Evidence context: Main Figs. 1–5
Experiment and dose: Cell reporter screen Caco-2 cells; Fluc mRNA 0.5 µg/mL | Readout and comparator: Readout: 18 h Comparator: Benchmark lipid formulations in the screen | Result and source: The screen identifies potent glucocorticoid-derived formulations. Reporter expression is a cell-assay endpoint, not colitis efficacy. Fig. 1; cell-transfection Methods
Experiment and dose: Rectal reporter delivery TNBS-colitis mice; Fluc mRNA; rectal 0.5 mg/kg with F127 | Readout and comparator: Readout: 6 h Comparator: SM-102 study formulation | Result and source: MP2 produces approximately 15-fold greater reported colonic reporter expression. Helper composition also differs between formulations. Fig. 1; n=3
Experiment and dose: Cell-type delivery Ai14 reporter mice; Cre mRNA; rectal 0.5 mg/kg on two consecutive days | Readout and comparator: Readout: Day 5 tissue assessment Comparator: Reporter controls | Result and source: Recombined reporter expression maps transfected cell populations. Cre recombination is not an IL-35 therapeutic outcome. Main Fig. 2; Methods
Experiment and dose: Chronic colitis Female IL-10-knockout mice; IL-35 mRNA; rectal 1 mg/kg once weekly, starting at 11 weeks of age | Readout and comparator: Readout: Endpoint at 18 weeks of age Comparator: SM-102–IL-35 and other study arms | Result and source: Reported disease activity index 0.38 for MP2–IL-35 versus 3.75 for SM-102–IL-35. This is an age-defined follow-up, not 18 weeks of treatment. Fig. 4; n=8; chronic-model Methods
Experiment and dose: Human tissue delivery Ex vivo IBD biopsy cultures; GFP mRNA 1 µg/well | Readout and comparator: Readout: 24 h Comparator: Ex vivo culture controls | Result and source: Expression was detected across immune, epithelial and endothelial populations. This is tissue-culture evidence, not dosing of patients. Fig. 5; human-biopsy Methods
Experiment and dose: Human tissue immune response Ex vivo Crohn’s-disease biopsy cultures; MP2–IL-35 | Readout and comparator: Readout: Study ex vivo endpoint Comparator: Study culture controls | Result and source: Reported changes include reduced Th1/Th17 populations and increased Treg populations. Donor and gating context is retained in the paper. Fig. 5; SI gating figures